查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301062

亨廷顿病治疗市场规模、份额和趋势分析报告：按疗法、最终用途、地区、细分市场趋势，2023-2030 年

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

亨廷顿病治疗市场增长和趋势

根据 GrandView Research, Inc. 的最新报告，到 2030 年，全球亨廷顿舞蹈症治疗市场预计将达到 18.712 亿美元。

从 2023 年到 2030 年，市场预计将以 23.20% 的复合年增长率扩张。 这一增长归因于西方国家对新产品开发、研究合作的高研发投入以及高HD负担。 亨廷顿舞蹈症是一种罕见的遗传性神经退行性疾□□病，影响几代人。 发病年龄为 30 岁至 50 岁，会损害工作和照顾家庭成员的能力，最终导致无法执行日常任务。

不同地区的患病率差异超过10倍，这被认为与病例掌握和诊断标准的差异有关。 不同地理位置的患病率差异超过 10 倍，这可能与病例识别和诊断标准的差异有关。 因此，一般人群中復发性肥大的患病率可能高于预期。 亚洲的患病率一直较低，而北美和澳大利亚的患病率较高。

Neurocrine Biosciences, Inc. 和 Azevan Pharmaceuticals, Inc. 等大公司专注于 HD 对症治疗的研究和开发。 Azevan Pharmaceuticals 正在开发 SRX246 作为治疗亨廷顿病神经精神症状的实验药物。 SRX246 是一种通过阻断大脑中加压素 1a (V1a) 受体发挥作用的药物。 在神经系统中，V1a 受体是主要的加压素受体。 通过抑制 V1a 受体，SRX246 限制加压素与受体的结合，导致亨廷顿病患者出现烦躁和攻击性行为。

然而，目前批准的药物是对症和姑息治疗，而不是治疗疾病的根本原因。 药物治疗虽然可以减轻症状的严重程度，但常伴有嗜睡、步态障碍、吞嚥困难、嗜睡等副作用，严重影响患者的生活质量。 鑑于这种疾病缺乏既定的治疗方法，评估这些患者的健康相关生活质量 (HRQOL) 受到的影响至关重要。 早期至中期疾病的 HD 患者需要多学科医疗服务，包括认知评估和咨询。

HD 的药物开发麵临重大障碍，一些治疗方法未能证明疗效或具有显着的毒性。 2020 年 9 月，Vaccinex Inc. 的 pepinemab 2 期试验未能在早期明显和前驱期 HD 患者中达到预先指定的共同主要终点。 在 SIGNAL 试验中，两个共同主要终点（亨廷顿认知评估电池和临床整体印像变化（CGIC）的两个认知终点）在早期症状人群中并未实现统计学显着性增加。

亨廷顿病治疗市场报告亮点

  • 由于产品可用性和专利保护，对症治疗领域在 2022 年的销售额中占据最大份额。 由于 SAGE-718 和 Cellavita-HD 的进入，疾病缓解疗法预计将成为预测期内增长最快的部分。
  • 公司现在不再针对突变蛋白，而是专注于开发通过将突变 HTT 蛋白直接注射到大脑中来直接阻断突变 HTT 蛋白形成的疗法。
  • 早期开发的新靶点药物包括Cellavita和Azidus Brazil的Cellavita HD（干细胞疗法）、Sangamo Therapeutics的mHTT ZFP（锌指蛋白）、AMT-130（UniQure的基因疗法）等。
  • 北美地区将在 2022 年占据最高的收入份额，并且由于美国和加拿大强大的报销体係以及沉重的 HD 负担，该地区将在预测期内继续主导市场。

内容

第一章调查方法及范围

  • 市场细分和范围
  • 区域范围
  • 估计/预测时间表
  • 目的
  • 调查方法
  • 信息获取
  • 信息或数据分析
  • 市场形成和验证
  • 型号详细信息
  • 辅助信息列表
  • 缩写列表

第 2 章执行摘要

  • 市场概况
  • 片段快照
  • 竞争格局快照

第三章市场变量、趋势和范围

  • 市场细分和范围
  • 市场体系展望
    • 母公司市场前景
    • 相关/辅助市场前景
  • 市场趋势和展望
  • 市场动态
    • 市场製约因素分析
    • 市场製约因素分析
  • 商业环境分析
    • SWOT 分析；按因素（政治/法律、经济/技术）
    • 波特五力分析

第四章产品业务分析

  • 亨廷顿病治疗市场：治疗波动分析
  • 对症治疗
  • 疾病缓解疗法

第 5 章最终用户业务分析

  • 亨廷顿病治疗市场：最终用户差异分析
    • 医院药房
    • 零售药店
    • 电子商务

第 6 章区域业务分析

  • 2022 年和 2030 年亨廷顿病治疗市场份额（按地区）
  • 北美
    • SWOT分析
    • 北美亨廷顿病治疗市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • SWOT分析
    • 2018-2030 年欧洲亨廷顿病治疗市场
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • SWOT分析
    • 2018-2030 年亚太地区亨廷顿舞蹈病治疗市场
    • 中国
    • 印度
    • 韩国
    • 澳大利亚
    • 泰国
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲亨廷顿病治疗市场，2018-2030 年
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • SWOT分析
    • MEA 亨□□廷顿病治疗市场，2018-2030 年
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第7章竞争格局

  • 公司分类
  • 战略规划
  • 2022 年主要参与者的市场份额分析
  • 公司简介
    • H. LUNDBECK A/S
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • BAUSCH HEALTH COMPANIES INC.
    • HETERO
    • LUPIN
    • HIKMA PHARMACEUTICALS PLC
    • DR. REDDY'S LABORATORIES LTD.
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
Product Code: GVR-2-68038-552-6

Huntington's Disease Treatment Market Growth & Trends

The global Huntington's disease treatment market size is expected to reach USD 1,871.2 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 23.20% from 2023 to 2030. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.

The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.

The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.

However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient's quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.

Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.

Huntington's Disease Treatment Market Report Highlights

  • The symptomatic treatment segment accounted for the largest revenue share in 2022 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
  • Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
  • Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy)
  • North America held the highest revenue share in 2022 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Treatment Segment
      • 1.1.1.2 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends And Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Market Restraint Analysis
      • 3.4.1.1. Strong Product Pipeline
      • 3.4.1.2. Disease Burden Of Huntington's In Developed Countries
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Significant Challenges And Unmet Needs In Huntington's Disease Treatment
      • 3.4.2.2. High Failure Rate In Clinical Trials
  • 3.5. Business Environment Analysis
    • 3.5.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Product Business Analysis

  • 4.1 Huntington's Disease Treatment Market: Treatment Movement Analysis
  • 4.2 Symptomatic Treatment
    • 4.2.1 Symptomatic Treatment Market, 2018 - 2030 (USD Million)
  • 4.3 Disease-Modifying Therapies
    • 4.3.1 Disease-Modifying Therapies Market, 2018 - 2030 (USD Million)

Chapter 5. End User Business Analysis

  • 5.1 Huntington's Disease Treatment Market: End User Movement Analysis
    • 5.1.1 Hospital Pharmacy
      • 5.1.1.1 Hospital Pharmacy market estimates and forecast, 2018 - 2030
    • 5.1.2 Retail Pharmacy
      • 5.1.2.1 Retail Pharmacy market estimates and forecast, 2018 - 2030
    • 5.1.3 E-Commerce
      • 5.1.3.1 E-Commerce market estimates and forecast, 2018 - 2030

Chapter 6. Regional Business Analysis

  • 6.1. Huntington's Disease Treatment Market Share By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. SWOT Analysis
    • 6.2.2. North America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. Reimbursement Scenario
      • 6.2.3.6. U.S. Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Competitive Scenario
      • 6.2.4.4. Regulatory Framework
      • 6.2.4.5. Reimbursement Scenario
      • 6.2.4.6. Canada Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Swot Analysis
    • 6.3.2. Europe Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. Reimbursement Scenario
      • 6.3.3.6. Germany Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.4. UK
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Reimbursement Scenario
      • 6.3.4.6. UK Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. Reimbursement Scenario
      • 6.3.5.6. France Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Reimbursement Scenario
      • 6.3.6.6. Italy Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Reimbursement Scenario
      • 6.3.7.6. Spain Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Reimbursement Scenario
      • 6.3.8.6. Denmark Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Reimbursement Scenario
      • 6.3.9.6. Sweden Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Target Disease Prevalence
      • 6.3.10.3. Competitive Scenario
      • 6.3.10.4. Regulatory Framework
      • 6.3.10.5. Reimbursement Scenario
      • 6.3.10.6. Norway Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Swot Analysis
    • 6.4.2. Asia Pacific Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Reimbursement Scenario
      • 6.4.3.6. Japan Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. Reimbursement Scenario
      • 6.4.4.6. China Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. Reimbursement Scenario
      • 6.4.5.6. India Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Reimbursement Scenario
      • 6.4.6.6. South Korea Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.7. Australia
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Reimbursement Scenario
      • 6.4.7.6. Australia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.8. Thailand
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Competitive Scenario
      • 6.4.8.4. Regulatory Framework
      • 6.4.8.5. Reimbursement Scenario
      • 6.4.8.6. Thailand Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. SWOT Analysis
    • 6.5.2. Latin America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Reimbursement Scenario
      • 6.5.3.6. Brazil Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Reimbursement Scenario
      • 6.5.4.6. Mexico Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Regulatory Framework
      • 6.5.5.5. Reimbursement Scenario
      • 6.5.5.6. Argentina Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. SWOT Analysis
    • 6.6.2. MEA Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. Reimbursement Scenario
      • 6.6.3.6. South Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Reimbursement Scenario
      • 6.6.4.6. Saudi Arabia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. Reimbursement Scenario
      • 6.6.5.6. UAE Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Regulatory Framework
      • 6.6.6.5. Reimbursement Scenario
      • 6.6.6.6. Kuwait Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1 Company Categorization
  • 7.2 Strategy Mapping
    • 7.1.1. New Product Launch
    • 7.1.2. Partnerships
    • 7.1.3. Acquisition
    • 7.1.4. Collaboration
    • 7.1.5. Funding
  • 7.3 Key Company Market Share Analysis, 2022
  • 7.4 Company Profiles
    • 7.4.1 H. LUNDBECK A/S
      • 7.4.1.1 Company overview
      • 7.4.1.2 Financial performance
      • 7.4.1.3 Product benchmarking
      • 7.4.1.4 Strategic Initiatives
    • 7.4.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 7.4.2.1 Company overview
      • 7.4.2.2 Financial performance
      • 7.4.2.3 Product benchmarking
      • 7.4.2.4 Strategic Initiatives
    • 7.4.3 BAUSCH HEALTH COMPANIES INC.
      • 7.4.3.1 Company overview
      • 7.4.3.2 Financial performance
      • 7.4.3.3 Product benchmarking
      • 7.4.3.4 Strategic Initiatives
    • 7.4.4 HETERO
      • 7.4.4.1 Company overview
      • 7.4.4.2 Product benchmarking
      • 7.4.4.3 Strategic Initiatives
    • 7.4.5 LUPIN
      • 7.4.5.1 Company overview
      • 7.4.5.2 Financial performance
      • 7.4.5.3 Product benchmarking
      • 7.4.5.4 Strategic Initiatives
    • 7.4.6 HIKMA PHARMACEUTICALS PLC
      • 7.4.6.1 Company overview
      • 7.4.6.2 Financial performance
      • 7.4.6.3 Product benchmarking
      • 7.4.6.4 Strategic Initiatives
    • 7.4.7 DR. REDDY'S LABORATORIES LTD.
      • 7.4.7.1 Company overview
      • 7.4.7.2 Financial performance
      • 7.4.7.3 Product benchmarking
      • 7.4.7.4 Strategic Initiatives
    • 7.4.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 7.4.8.1 Company overview
      • 7.4.8.2 Financial performance
      • 7.4.8.3 Product benchmarking
      • 7.4.8.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Huntington's Disease Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 6 Global Huntington's Disease Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 9 North America Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 11 U.S. Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 12 Canada Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 13 Canada Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 14 Europe Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 16 Europe Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 17 Germany Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 18 Germany Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 19 UK Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 20 UK Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 21 France Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 France Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 23 Italy Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 24 Italy Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 25 Spain Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 26 Spain Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 27 Denmark Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 28 Denmark Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 29 Sweden Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 30 Sweden Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 31 Norway Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 32 Norway Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 36 China Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 37 China Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 38 Japan Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 39 Japan Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 40 India Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 41 India Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 42 South Korea Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 43 South Korea Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 44 Australia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 45 Australia Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 46 Thailand Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 47 Thailand Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 48 Latin America Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 50 Latin America Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 51 Brazil Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 52 Brazil Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 53 Mexico Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 54 Mexico Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 55 Argentina Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 Argentina Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 60 South Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 61 South Africa Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 64 UAE Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 UAE Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain - Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Huntington's Disease Treatment Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Huntington's Disease Treatment Market: by Treatment Movement Analysis
  • Fig. 15 Global Huntington's Disease Treatment Market, for Symptomatic treatment, 2018 - 2030 (USD Million)
  • Fig. 16 Global Huntington's Disease Treatment Market, for Disease - modifying therapies, 2018 - 2030 (USD Million)
  • Fig. 17 Global Huntington's Disease Treatment Market: End use Movement Analysis
  • Fig. 18 Global Huntington's Disease Treatment Market, for Pharmaceutical & Biotechnology Companies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Huntington's Disease Treatment Market, for Hospital pharmacy, 2018 - 2030 (USD Million)
  • Fig. 20 Global Huntington's Disease Treatment Market, for Retail pharmacy, 2018 - 2030 (USD Million)
  • Fig. 21 Global Huntington's Disease Treatment Market, for E - commerce, 2018 - 2030 (USD Million)
  • Fig. 22 Regional Marketplace: Key Takeaways Huntington's Disease Treatment Market, Region 2018 - 2030 (USD Million)
  • Fig. 23 Huntington's Disease Treatment Market :Regional Outlook, 2022 & 2030 2018 - 2030 (USD Million)
  • Fig. 24 North America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 26 Canada Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 27 Europe Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 29 UK Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 30 France Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 31 Italy Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 32 Spain Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 33 Denmark Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 34 Sweden Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 35 Norway Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 Japan Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 38 China Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 India Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 40 Australia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 42 Thailand Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 48 South Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 49 Saudi Arabia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 50 UAE Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)